The U.S. Food and Drug Administration (FDA) clears C2N Diagnostics’ PrecivityAD2 blood test to help diagnose Alzheimer’s disease as part of a standard clinical workup, the company says. The test is intended to detect indicators of Alzheimer’s pathology from a blood sample.
Multiple outlets describe the clearance as a step toward scalable, blood-based diagnostic testing. PR Newswire emphasizes that the test is the first Alzheimer’s blood test cleared for patients as young as 40, and links the milestone to long-term investment connected to the Alzheimer’s Drug Discovery Foundation (ADDF). MedPage Today focuses on the clinical framing of the clearance and the test’s approach, reporting that PrecivityAD2 measures plasma amyloid beta and tau peptide ratios.
While sources align on the FDA clearance and the general purpose of the test, they differ in emphasis: PR Newswire highlights access and investment context, while MedPage Today highlights how the test works and its role in routine clinical evaluation.
